Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter study of GZR101-80 injection in adults with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or prior basal insulin
CTR20253679Phase 2Active
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Apr 2026
- Modality
- Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GZR101 in type 2 diabetes mellitus (T2DM), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Change from baseline in glycated hemoglobin. Started Apr 2026; status: active.
02
Drugs
GZR101
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20253679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253679.